MBK Partners' Opposite K-Beauty Bets: AXIS-Y and Skin Idea
Updated: 4 hours ago
Between 2 and 7 September 2026, MBK Partners put roughly 470 billion won ($349 million) into two Korean beauty assets. One is a control buyout of Skin Idea and Life&Bio at about 300 billion won ($223 million), near eight times combined EBITDA. The other is 172 billion won ($128 million) for 40% of AXIS-Y's parent at a 430 billion won ($320 million) valuation, founder still in control. Korea's largest buyout firm bought the cash and the option at once, and has not decided which one K-beauty is.
What did MBK Partners sign in the first week of September?
The first transaction became public on 2 September. MBK Partners' Special Situations division — the arm that ordinarily writes mezzanine and minority cheques rather than buying companies outright — agreed to acquire 67% of Skin Idea and 81% of Life&Bio from Morgan Stanley Private Equity for approximately 300 billion won ($223 million; dollar figures throughout convert at 1,345.9 won per dollar, the 11 September 2026 close). The share purchase agreement was signed in August. Skin Idea operates the derma-aesthetic brands Medifill and Derma Maison, and reported revenue of 104.5 billion won ($78 million) and EBITDA of 27.5 billion won ($20 million). Life&Bio, a health-supplement business that has itself acquired the food company FoodCare, reported consolidated revenue of 44.2 billion won ($33 million) and EBITDA of 6.9 billion won ($5.1 million). Existing management stays in place at both.
EBITDA — earnings before interest, taxes, depreciation and amortisation — is the standard proxy for the cash a business throws off before financing and accounting choices. Combined, the two companies produce 34.4 billion won ($26 million) of it. Against a 300 billion won ($223 million) price, that is 8.7 times, and reports describe the pricing as roughly eight times.
The second transaction was announced on 7 September. MBK agreed to take 40% of Asia Master Trade, the company behind the brand AXIS-Y, for approximately 172 billion won ($128 million) at a valuation of about 430 billion won ($320 million). The founder retains 60% and operational control. AXIS-Y was founded in 2019, draws more than 90% of revenue from outside Korea, sells in roughly 100 countries, and entered Olive Young — Korea's dominant health-and-beauty chain — only in 2025. By the company's own announcement, its Dark Spot Correcting Glow Serum has sold more than 20 million units cumulatively. MBK is its first institutional investment partner.
Why are these two deals structurally opposite?
A control buyout and a minority growth investment are not two sizes of the same thing. They answer different questions and they pay for different risks.
In a control buyout the acquirer owns the outcome. It sets the capital structure, replaces or keeps management, decides when and how to exit, and underwrites the price against cash the business already generates. The discipline shows up in the multiple: eight times EBITDA on a domestic derma and wellness platform is a price that works if the earnings hold, and it does not require the business to become something it is not.
In a minority growth investment the acquirer owns a claim on someone else's execution. MBK does not control AXIS-Y, cannot direct it, and is paid only if the founder keeps compounding the brand. The 430 billion won ($320 million) valuation is not supported by a disclosed EBITDA figure at all. It is supported by a market position — roughly 100 countries, more than 90% of revenue earned abroad — and by a judgment about how long that position lasts.
Same firm, same week, same sector, opposite risk. One deal says K-beauty is an earnings stream to be bought at a defensible multiple. The other says it is an equity story with a long runway. Those are not complementary theses. They are alternatives, and holding both is a statement that the question is open.
What does an eight-times price say about the asset being bought?
It says the buyer treated the business as a going concern rather than a growth narrative. Eight times EBITDA is the kind of number that clears an investment committee on downside arithmetic: the earnings cover the price within a decade of flat performance, and any growth is upside rather than the basis of the case.
MBK's stated rationale points the same direction. The firm cited structural growth in domestic wellness — an ageing population, rising incomes, and increasing spend on prevention rather than treatment. That is a demographic argument about Korean consumers at home, not an export argument. Skin Idea and Life&Bio are being bought for what Koreans will keep spending on inside Korea.
Note what this pricing implies about the seller's position too. A disciplined multiple on a business with 34.4 billion won ($26 million) of EBITDA is a transaction that both sides can defend. Nobody in it is paying for a story.
What is MBK buying when it pays 430 billion won for a brand founded in 2019?
Distribution reach that took seven years to build and would take longer to replicate. AXIS-Y sells in roughly 100 countries with more than 90% of revenue earned outside Korea, which means the brand has already solved the problem most Korean beauty companies are still working on: demand that does not depend on one market, one retailer, or one platform algorithm.
What the valuation does not rest on is a disclosed earnings base. No revenue or EBITDA figure for Asia Master Trade appears in the announcement, and the 20-million-unit figure for its lead serum comes from the company itself rather than an audited disclosure. An investor paying 430 billion won ($320 million) on that information set is pricing the brand's position, not its current profit.
That is a defensible thing to pay for. It is not what the other deal paid for, and it also explains the structure. Leaving the founder with 60% and control is how a financial investor buys exposure to brand momentum without taking responsibility for producing it.
Why does a brand with 90% overseas revenue reach Olive Young last?
Because the standard Korean sequence has been inverted. The conventional path runs domestic first: launch into Olive Young, accumulate sell-through data, use that record to convince foreign buyers and distributors, then export. Domestic validation functions as the credential.
AXIS-Y ran the sequence backwards, building overseas demand from 2019 and entering Olive Young only in 2025. The contract-manufacturing base is what makes that possible — Korea's ODM tier lets a small team develop, formulate and ship a competitive product without owning a factory or holding domestic shelf space. What had not happened until now is institutional capital putting a 430 billion won ($320 million) valuation on a company that skipped the credential entirely.
That is the structural content of the AXIS-Y deal, and it travels beyond this one brand. Domestic retail performance has functioned as the entry ticket to serious valuation conversations in Korean beauty. One deal does not end that convention. It does establish a reference point for founders who never had the ticket.
Who is selling, and why does that matter more than who is buying?
The buyer generated the headlines. The seller carries the information. Morgan Stanley Private Equity acquired 81% of Life&Bio in 2021 for approximately 80 billion won ($59 million) and 67% of Skin Idea in 2024 at a valuation of about 150 billion won ($111 million). With this sale, its Korean buyout portfolio is empty.
A global fund is stepping out of Korean beauty ownership at a point when Korean cosmetics exports are at record levels, and a Korean fund is stepping in. That is a rotation of ownership, not a verdict on the sector: both sides looked at the same assets and the same cycle and reached opposite conclusions about what to do next. One of them is wrong, and which one will be visible in the exit multiple three to five years from now rather than in any statement made currently.
For anyone selling into or sourcing from these companies, the practical consequence is narrower and more immediate. Ownership has moved from a foreign fund with a global mandate to a domestic fund with a Korean wellness thesis. Capital allocation, category priorities and partner selection get decided in Seoul now.
What can and cannot be concluded about the seller's return?
Less than the numbers invite. The entry figures and the exit figure are reported on different bases: 80 billion won ($59 million) as the price for a stake in 2021, about 150 billion won ($111 million) as a company valuation in 2024, and about 300 billion won ($223 million) as the combined price for controlling stakes in both businesses in 2026. Those three numbers do not subtract into a return.
No outlet reports a realised return, an IRR or a money multiple for Morgan Stanley PE on either asset, and the disclosed information does not permit one to be calculated — holding periods differ, the stakes differ, intervening capital flows are not disclosed, and Life&Bio acquired FoodCare during the holding period, which changes the business that is being sold from the one that was bought.
The defensible statement is the plain one: a fund that entered in 2021 and 2024 exited in 2026, in a single package, to a domestic buyer, at a disclosed price of about 300 billion won ($223 million). Everything past that is arithmetic performed on incompatible figures.
What does a portfolio holding both bets say about K-beauty as an asset class?
Three readings are available, and the transactions support all three.
The first: K-beauty has matured into two separable asset types, and a large fund is correct to own one of each — domestic wellness platforms priced on earnings, and born-global brands priced on reach. On this reading the five-day pairing is portfolio construction, not indecision.
The second: the pairing is a hedge, and hedges are what investors build when conviction is thin. A fund that knew whether K-beauty's durable value sits in manufacturing-backed brands or in domestic consumption would concentrate rather than split 470 billion won ($349 million) across opposite structures.
The third, and the one the numbers support most directly: the difference between the two deals is not the sector, it is what each seller would accept. A global fund exiting its last Korean assets sold control at eight times earnings. A founder with 90% of revenue offshore sold 40% and kept the keys. The structure followed the seller's position, not the buyer's thesis.
Korean beauty assets are now priced two ways in the same week by the same firm. The earnings-based price is the one that can be checked. The other one is a claim about how long a brand's reach lasts, and that claim gets settled by the next buyer, not by this one.
Comments